Loading company…
NeuroDerm develops drug-device therapies for central nervous system disorders, particularly Parkinson's disease.
NeuroDerm develops drug-device therapies for central nervous system disorders, with a focus on Parkinson's disease. Its ND0612 system delivers levodopa/carbidopa by continuous subcutaneous infusion and is in late-stage development. Founded in 2003, the company is based in Rehovot, Israel. Its November 2014 IPO raised USD 45.00 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in